Brokerages Set Haleon PLC Sponsored ADR (NYSE:HLN) PT at $12.33

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $12.3250.

Several research firms have recently commented on HLN. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Hsbc Global Res raised Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research note on Tuesday. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HLN. Brighton Jones LLC purchased a new stake in Haleon in the 4th quarter valued at about $187,000. AQR Capital Management LLC grew its holdings in shares of Haleon by 22.5% in the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after acquiring an additional 17,720 shares in the last quarter. Focus Partners Wealth increased its position in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after acquiring an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. Finally, Rhumbline Advisers boosted its position in Haleon by 6.7% in the first quarter. Rhumbline Advisers now owns 57,527 shares of the company’s stock worth $592,000 after purchasing an additional 3,625 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

NYSE HLN opened at $10.45 on Wednesday. The company has a market cap of $46.51 billion, a P/E ratio of 26.78 and a beta of 0.19. The company has a fifty day simple moving average of $9.86 and a 200 day simple moving average of $9.61. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon has a 12-month low of $8.71 and a 12-month high of $11.42.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.